"Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia

Cancer Genetics and Cytogenetics

Volumn 174, Issue 2, 2007, Pages 121-126

  Albano, Francesco ^a   Anelli, Luisa ^a   Zagaria, Antonella ^a   Archidiacono, Nicoletta ^a   Liso, Vincenzo ^a   Specchia, Giorgina ^a   Rocchi, Mariano ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CANCER PATIENT; CHROMOSOME 22; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; COMPLEX FORMATION; DIAGNOSTIC PROCEDURE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE PROBE; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; METHODOLOGY; MOLECULAR WEIGHT; PRIORITY JOURNAL;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; DNA PROBES; FUSION PROTEINS, BCR-ABL; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOID, CHRONIC; REPRODUCIBILITY OF RESULTS; TRANSLOCATION, GENETIC;

EID: 34247100205     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2006.09.025     Document Type: Article

References (18)

1. Nowell P., and Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 132 (1960) 1497
2. Rowley J.D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
3. Shtivelman E., Lifshitz B., Gale R.P., and Canaani E. Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia. Nature 315 (1985) 550-554
4. Johansson B., Fioretos T., and Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107 (2002) 76-94
5. Mitelman F, Johansson B, Mertens F, editors. 2005. Mitelman Database of Chromosome Aberrations in Cancer. Available at: http://www.cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed August 30, 2006.
6. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-743
7. Cohen N., Rozenfeld-Granot G., Hardan I., Brok-Simoni F., Amariglio N., Rechavi G., and Trakhtenbrot L. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene. Expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 128 (2001) 114-119
8. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic factor in chronic myeloid leukaemia. Blood 98 (2001) 1732-1738
9. Kolomietz E., Al-Maghrabi J., Brennan S., Karaskova J., Minkin S., Lipton J., and Squire J.A. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 97 (2001) 3581-3588
10. Storlazzi C.T., Specchia G., Anelli L., Albano F., Pastore D., Zagaria A., Rocchi M., and Liso V. Breakpoint characterization of der(9) deletions in CML patients. Genes Chromosomes Cancer 35 (2002) 271-276
11. Huntly B.J., Bench A., and Green A.R. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 102 (2003) 1160-1168
12. Albano F., Specchia G., Anelli L., Zagaria A., Storlazzi C.T., Buquicchio C., Roberti M.G., Liso V., and Rocchi M. Genomic deletions on other chromosomes involved in variant t(9;22) chronic myeloid leukemia cases. Genes Chromosomes Cancer 36 (2003) 353-360
13. Specchia G., Albano F., Anelli L., Storlazzi C.T., Zagaria A., Liso A., Pannunzio A., Pastore D., Mestice A., Greco G., Liso V., and Rocchi M. Derivative chromosome 9 deletions in chronic myeloid leukemia are associated with loss of tumor suppressor genes. Leuk Lymphoma 45 (2004) 689-694
14. Lichter P., Tang Chang C.J., Call K., Hermanson G., Evans G.A., Housman D., and Ward D.C. High resolution mapping of human chromosomes 11 by in situ hybridization with cosmid clones. Science 247 (1990) 64-69
15. Huntly B., Bench A., Delabesse E., Reid A.G., Li J., Scott M.A., Campbell L., Byrne J., Pinto E., Brizard A., Niedermeiser D., Nacheva E.P., Guilhot F., Deininger M., and Green A.R. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels or karyotypic instability. Blood 99 (2002) 4547-4553
16. Huntly B., Guilhot F., Reid A.G., Vassiliou G., Hennig E., Franke C., Byrne J., Brizard A., Niederwieser D., Freeman-Edward J., Cuthbert G., Bown N., Clark R.E., Nacheva E.P., Green A.R., and Deininger M.W. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 102 (2003) 2205-2212
17. Aoun P., Wiggins M., Pickering D., Foran J., Rasheed H., Pavletic S.Z., and Sanger W. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis. Cancer Genet Cytogenet 154 (2004) 138-143
18. Yoong Y., VanDeWalker T.J., Carlson R.O., Dewald G.W., and Tefferi A. Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia. Eur J Haematol 74 (2005) 124-127